Canada Approves Celltrion’s Remsima SC Biosimilar
Company Plans to Expand From Initial RA Indication To Also Cover IBD
Health Canada has approved Celltrion’s subcutaneous version of Remsima for rheumatoid arthritis, as Celltrion plans to expand indications for the infliximab biosimilar to allow it to also treat inflammatory bowel disease. The company has also established an offshoot in Canada that will allow it to sell Remsima SC directly.
